Miguel Regueiro

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Dr. Sara Horst MD, MPH, FACG, AGAF is a Professor in the division of Gastroenterology, Hepatology, & Nutrition at Vanderbilt University Medical Center. Dr. Horst completed her medical school and residency training at The Ohio State University and then went to Vanderbilt University Medical Center for Gastroenterology Fellowship and to obtain her Masters of Public Health. She joined the faculty at Vanderbilt University Medical Center in 2011. She is involved in clinical care of complex IBD care, complex amyloid care, clinical research, and teaching and mentoring medical students and housestaff. She is the medical director for VUMC Specialty Pharmacy, VUMC Telehealth director, and VUMC Associate Vice Chair of Clinical Affairs for Dept of Medicine. Her research interests involve enhancing EHR efficiencies in the care of IBD, telehealth in IBD, and medication adherence in IBD. She has extensively published in peer reviewed journals. She is also involved in clinical care improvement as an EPIC Physician Builder and is on the National EPIC GI Steering Board. She is an associate editor for American Journal of Gastroenterology.

Edward V. Loftus, Jr. is a gastroenterologist who specializes in the care of patients with complex Crohn's disease and ulcerative colitis. He is the Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically in IBD at Mayo Clinic College of Medicine and Science in Rochester, Minnesota, USA. He developed a population-based cohort of inflammatory bowel disease patients which has resulted in over 50 peer-reviewed publications on the epidemiology and natural history of IBD. Professor Loftus has published over 500 original articles, book chapters, or editorials and more than 750 abstracts. He was awarded AGA’s Distinguished Clinician Award and the IMIBD section’s Research Mentor Award in 2019. He has also been awarded the Mayo Department of Medicine Laureate Award twice and the Outstanding Mentorship Award in Research. Professor Loftus has been the principal investigator on several funded studies focusing on the epidemiology and natural history of inflammatory bowel disease and has served as the local PI on multiple clinical trials of investigational agents for IBD. He serves on the steering committees of several clinical development programs in IBD. In the past he has served as Associate Editor for American Journal of Gastroenterology and Inflammatory Bowel Diseases, and currently serves as Associate Editor for Clinical Gastroenterology and Hepatology.

Laura Raffals, MD, MS, FACG is Professor of Medicine, Vice Chair, Department of Medicine at Mayo Clinic, Rochester, MN. She received her Masters in Health Studies and completed her gastroenterology fellowship training at the University of Chicago, and for six years was a member of the faculty. In 2011, she joined the Gastroenterology and Hepatology Division at Mayo Clinic. Dr. Raffals’ clinical and research interests have focused on inflammatory bowel disease with a focus on pouch disorders, exploring the intersection of pouch motility disorders and pouch inflammation. She is the co-principal investigator for the Crohn’s and Colitis Foundation SPARC IBD, a national prospective adult research cohort with IBD study and has published broadly on topics in inflammatory bowel disease.

Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Sands is an expert in the management of IBD and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his BA and MD from Boston University, and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island. Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn's & Colitis Foundation of America and served as Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the Chair of the International Organization for the Study of IBD (IOIBD). In 2016 Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s & Colitis Foundation of America, that organization’s highest honor.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Dr. Grossman is the Associate Clinic Chief of Gastroenterology, Hepatology, and Nutrition and Co-Director of the Center for Pediatric Inflammatory Bowel Disease at the Children’s Hospital of Philadelphia and the Robert N. Baldassano MD Professor of Clinical Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Grossman has dedicated his career to advancing the quality of clinical care and promoting a multidisciplinary approach for children and adolescents with IBD. He has led national committees for the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and ImproveCareNow (ICN). He has been involved with the Crohn’s & Colitis Foundation for years, serving on the Board of Directors and the Chapter Medical Advisory Committee for the Philadelphia/Delaware Valley chapter, as well as serving as chair of the Pediatric Affairs Committee on the National Scientific Advisory Committee (NSAC). He has co-authored multiple research publications, is an editor of the Pediatric Inflammatory Bowel Disease textbook, and frequently lectures at national scientific meetings.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Dr. Cohen is a Staff Physician and Co-Section Head and Clinical Director for Inflammatory Bowel Diseases in the Department of Gastroenterology, Hepatology, and Nutrition at the Cleveland Clinic, Cleveland, OH. Throughout his career, Dr. Cohen has merged clinical care with participation in inflammatory bowel disease (IBD) clinical research. His primary research interest has been centered on the safety of biologic medications in the peri-operative period for which he led PUCCINI, a large multi-center clinical study. Dr. Cohen has also been a site primary investigator on Phase 3 IBD pharmaceutical clinical trials and collaborative investigator initiated studies. In addition to his research interests, Dr. Cohen also has a strong commitment to IBD education. He has been a member of the Crohn’s & Colitis Foundation Professional Education Committee and a co-founder and former chair of Rising Educators Academics and Clinicians Helping IBD (REACH-IBD); a special committee within the Crohn’s & Colitis Foundation of America for trainees and junior faculty to promote collaboration, mentorship, and career advancement. The Crohn’s and Colitis Foundation recognized him for his leadership with the Rising Star award in 2018. He currently serves on the Crohn's and Colitis Foundation NSAC as the Chair of Professional Membership. Dr. Cohen has also been an active member of the American Gastroenterological Association (AGA) serving on both the Education and Training Committee and Clinical Guidelines Committee.

Parambir S. Dulai, MD, is a board-certified gastroenterologist with clinical and research expertise in inflammatory bowel disease (IBD). Dr. Dulai is a proud recipient of the 2022 Sherman Emerging Leader Prize by The Bruce and Cynthia Sherman Charitable Foundation that recognizes outstanding achievements in IBD. He is an Associate Professor of Medicine at Northwestern University where he also serves as Director of Precision Medicine for the Division of Gastroenterology and Hepatology. Dr. Dulai completed his medical school training at Dayanand Medical College in Ludhiana, Punjab, India, and subsequently completed his internal medicine residency and chief residency at Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. He then went on to complete an NIH sponsored T32 research fellowship and IBD clinical fellowship at the University of California San Diego, La Jolla, CA, USA. He spent an additional year of advanced training in clinical trials with Robarts Clinical Trials and in 2019 he was the recipient of the American Gastroenterology Association (AGA) research scholar award focused on personalized medicine. He has a successful NIH funded research program focused on real world evidence generation, clinical trials, and integrating evolving translational technology into mechanism of action studies.

Phillip R. Fleshner, MD is the Director of Colorectal Surgery Research at Cedars-Sinai Medical Center. He holds the Shierley, Jesslyne, and Emmeline Widjaja Chair in Colorectal Surgery.

Dr. Fleshner's main clinical and research interests are directed towards optimizing outcomes and techniques in the surgical management of Crohn's disease and ulcerative colitis.

Dr. Fleshner has written numerous articles for peer-reviewed publications, including the Annals of Surgery, Journal of the American College of Surgeons, Diseases of the Colon and Rectum, Gut and the American Journal of Surgery.

Dr. Fleshner received his bachelor's degree from McGill University and his medical degree from the Albert Einstein College of Medicine. He completed his General Surgery Residency at the Mount Sinai Medical Center in New York and his Colorectal Surgery Fellowship at the Lahey Clinic in Boston.

He received the Sherman Prize in 2021.

Dr. Christina Ha completed her internal medicine residency and fellowship at the Washington University in St. Louis School of Medicine and then received additional training as the Present-Levison Inflammatory Bowel Diseases Fellow at the Mount Sinai School of Medicine. She is Director of the Inflammatory Bowel Disease Section and Associate Professor of Medicine at Mayo Clinic Arizona. Her clinical research interests focus on the impact of aging on the natural history of the inflammatory bowel diseases, especially the pathogenesis and natural history of late-onset IBD. She is also very involved in IBD related trainee educational initiatives and has served on multiple committees within the Crohn’s and Colitis Foundation, American College of Gastroenterology, and American Gastroenterological Association.

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Neilanjan Nandi, MD, FACG, AGAF, FCCF, FACP is an Associate Professor of Clinical Medicine at the Perelman School of Medicine, University of Pennsylvania and is the Co-Section Head and Direcotr of Clinical Operations of the University of Pennsylvania Inflammatory Bowel Disease Program. Dr. Nandi specializes in the complex management of Crohn's disease, Ulcerative Colitis and recurrent C. difficile infection (C difficile). He has also authored numerous abstracts, publications and book chapters on the diagnosis and management of IBD, C difficile and various viral, parasitic, mycobacterial and bacterial infections of the GI tract. Aligning with his interests, Dr. Nandi has conducted several clinical trials focused on the clinical impact of stool derived microbiome therapies in C difficile and IBD. Dr. Nandi servies on the Philadelphia/Delaware Valley Crohn's & Colitis Foundation (CCF) Executive Council and on the Medical Advisory Board of the United Ostomy Associates of America (UOAA). He is a founding non-profit board member and Chair of the South Asian IBD Alliance (SAIA) which elevates culturally competent care in South Asian IBD. He has been recognized with the 2019 Philly Take STeps Physician Hero, the 2022 CCF's National Chairman’s Citation Award and the 2024 CCF's Gold Medallion Physician Award. He is the honored recipient of the 2023 Sidney Cohen GI Faculty Teaching Award and the 2024 Radhika Srinivasan GI Faculty award for Professionalism and Humanism at the Perelman School of Medicine.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Dr. Jean Ashburn is an Associate Professor of Surgery and a Faculty Colorectal surgeon at Atrium Health Wake Forest in Winston-Salem, NC. She is a graduate of Wake Forest University School of Medicine and finished her residency in General Surgery at the University of North Carolina at Chapel Hill. She then completed a fellowship in Colorectal Surgery at the Cleveland Clinic Foundation in Cleveland, Ohio, where she was a staff surgeon prior to joining the Department of Surgery at Wake Forest Baptist Medical Center. She has particular clinical and research interests in complex inflammatory bowel disease and J pouch surgery, reoperative pelvic surgery, and corrective/restorative surgery of the lower gastrointestinal tract.

Edward L. Barnes, MD, MPH is an Associate Professor of Medicine in the Division of Gastroenterology & Hepatology and Co-Director of the Multidisciplinary Inflammatory Bowel Diseases Center at the University of North Carolina of Chapel Hill. Dr. Barnes received his undergraduate and medical degrees from the University of South Carolina. He completed his internship, residency, and chief residency in internal medicine at the University of North Carolina. He completed his gastroenterology fellowship at Brigham and Women’s Hospital in Boston, Massachusetts. During his gastroenterology fellowship, Dr. Barnes received a Master of Public Health from the Harvard TH Chan School of Public Health. Following his gastroenterology fellowship, Dr. Barnes completed a one year advanced fellowship in inflammatory bowel disease at the University of North Carolina.

Dr. Barnes has a research interest in the epidemiology and clinical outcomes of patients with inflammatory bowel disease. He has a particular interest in improving our understanding of inflammatory conditions of the pouch after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). He has received funding from the National Institutes of Health, Crohn’s & Colitis Foundation, American College of Gastroenterology, and American Gastroenterological Association to study clinical outcomes of patients with pouchitis and other pouch-related conditions and to investigate predictors of a complicated disease course after IPAA. Dr. Barnes is the 2021 Sherman Emerging Leader Prize recipient.

Jami Kinnucan, MD, is an inflammatory bowel disease (IBD) specialist who joined the Mayo Clinic Florida practice in January 2021 as an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology. She currently serves as the Clinical Practice Chair for the Division of Gastroenterology & Hepatology, Associate Chair for Digital Transformation and Practice Integration for the Department of Medicine and Medical Director for Plummer Chart Ambulatory Communication Solutions team. She is also the Director of the IBD Intestinal Ultrasound Program at Mayo Clinic Florida. She has been recognized as a fellow of the American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), and Crohn's and Colitis Foundation. She is a former member of the ACG Board of Governors for the state of Michigan and the ACG Women in Gastroenterology Committee. She is active in the Crohn’s and Colitis Foundation and previous Co-Chair for the Women in IBD Task Force and prior member of the Government and Industry Affairs Committee for the National Scientific Advisory Committee. Dr. Kinnucan is the co-founder of the Michigan GI Society in 2020 and, most recently, co-founded the Florida Women in GI (2022) and Gastro Digital Health (2024) She serves as Associate Editor for the Crohn’s and Colitis 360 Journal. She is actively involved with research looking at the impact of cannabis in IBD and received a 2024 Mayo Clinic STARDOM award to evaluate the use of virtual reality on the impact of pain in patients with abdominal pain and Crohn’s disease.

James Lewis, MD, MSCE, is Professor of Medicine and Epidemiology, Senior Scholar in the Center for Clinical Epidemiology and Biostatistics, LDI Senior Fellow, Vice-Chief for Research (Clinical) in the Division of Gastroenterology and Hepatology at the University of Pennsylvania’s Perelman School of Medicine and Chief of Gastroenterology at Penn Presbyterian Medical Center in Philadelphia, Pennsylvania. Dr. Lewis is a gastroenterologist with a focus on caring for patients with inflammatory bowel diseases (IBD) and has conducted clinical research related to IBD for nearly 30 years. His reserach includes epidemiology studies focusing on optimal choice of therapies and treatment patterns and investigator-initiated multicenter clinical trials of medications and behavioral interventions, particulalry related to dietary patterns. His work has been funded by the NIH, AHRQ, CDC, PCORI, and numerous foundations and corporate sponsors. Dr. Lewis is the lead scientist for the Crohn's & Colitis Foundation’s IBD Plexus Research Program. He is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. In 2016, he received the Sherman Prize for Excellence in Crohn’s and Colitis.